Induction of apoptosis in pediatric acute lymphoblastic leukemia (ALL) cells by the therapeutic opioid methadone and effective synergy with Bcl-2 inhibition

Leukemia Research

Volumn 35, Issue 12, 2011, Pages 1649-1657

  Singh, Anjali ^a   Jayanthan, Aarthi ^a   Farran, Allyson ^a   Elwi, Adam N ^b   Kim, Sung Woo ^b   Farran, Peter ^a   Narendran, Aru ^a  

^a ALBERTA CHILDREN'S HOSPITAL   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

ABT 737; Apoptosis ; Bcl 2; Methadone; Pediatric leukemia

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; METHADONE; PROTEIN BCL 2; PROTEIN MCL 1;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CHILD; CONTROLLED STUDY; DRUG CYTOTOXICITY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; INFANT; LEUKEMIA CELL; MITOCHONDRION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN DEGRADATION; SCHOOL CHILD;

AGE FACTORS; AGE OF ONSET; ANALGESICS, OPIOID; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BIPHENYL COMPOUNDS; CHILD; CHILD, PRESCHOOL; DRUG EVALUATION, PRECLINICAL; DRUG SYNERGISM; FEMALE; HUMANS; INFANT; MALE; METHADONE; NITROPHENOLS; PIPERAZINES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRIMARY CELL CULTURE; PROTO-ONCOGENE PROTEINS C-BCL-2; SULFONAMIDES; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 80055109914     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.06.035     Document Type: Article

References (48)

1. Pieters R., Carroll W.L. Biology and treatment of acute lymphoblastic leukemia. Pediatr Clin North Am 2008, 55:1-20.
2. Maneckjee R., Minna J.D. Opioids induce while nicotine suppresses apoptosis in human lung cancer cells. Cell Growth Differ 1994, 5:1033-1040.
3. Maneckjee R., Minna J.D. Nonconventional opioid binding sites mediate growth inhibitory effects of methadone on human lung cancer cells. Proc Natl Acad Sci U S A 1992, 89:1169-1173.
4. Maneckjee R., Minna J.D. Opioid and nicotine receptors affect growth regulation of human lung cancer cell lines. Proc Natl Acad Sci U S A 1990, 87:3294-3298.
5. Perez-Alvarez S., Cuenca-Lopez M.D., de Mera R.M., Puerta E., Karachitos A., Bednarczyk P., et al. Methadone induces necrotic-like cell death in SH-SY5Y cells by an impairment of mitochondrial ATP synthesis. Biochim Biophys Acta 2010, 1802:1036-1047.
6. Friesen C., Roscher M., Alt A., Miltner E. Methadone, commonly used as maintenance medication for outpatient treatment of opioid dependence, kills leukemia cells and overcomes chemoresistance. Cancer Res 2008, 68:6059-6064.
7. Kostanová-Poliaková D., Sabová L. Anti-apoptotic proteins-targets for chemosensitization of tumor cells and cancer treatment. Neoplasma 2005, 52:441-449.
8. Lieber J., Kirchner B., Eicher C., Warmann S.W., Seitz G., Fuchs J., et al. Inhibition of Bcl-2 and Bcl-X enhances chemotherapy sensitivity in hepatoblastoma cells. Pediatr Blood Cancer 2010, 55:1089-1095.
9. Haarman E.G., Kaspers G.J., Pieters R., van Zantwijk C.H., Broekema G.J., Hählen K., et al. BCL-2 expression in childhood leukemia versus spontaneous apoptosis, drug induced apoptosis, and in vitro drug resistance. Adv Exp Med Biol 1999, 457:325-333.
10. Cory S., Adams JM Killing cancer cells by flipping the Bcl-2/Bax switch. Cancer Cell 2005, 8:5-6.
11. Lock R., Carol H., Houghton P.J., Morton C.L., Kolb E.A., Gorlick R., et al. Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. Pediatr Blood Cancer 2008, 50:1181-1189.
12. Gandhi L., Camidge D.R., Ribeiro de Oliveira M., Bonomi P., Gandara D., Khaira D., et al. Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors. J Clin Oncol 2011, 29:906-916.
13. Tahir S.K., Wass J., Joseph M.K., Devanarayan V., Hessler P., Zhang H., et al. Identification of expression signatures predictive of sensitivity to the Bcl-2 family member inhibitor ABT-263 in small cell lung carcinoma and leukemia/lymphoma cell lines. Mol Cancer Ther 2010, 9:545-557.
14. Yecies D., Carlson N.E., Deng J., Letai A. Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood 2010, 115:3304-3313.
15. Jayanthan A., Incoronato A., Singh A., Blackmore C., Bernoux D., Lewis V., et al. Cytotoxicity, drug combinability, and biological correlates of ABT-737 against acute lymphoblastic leukemia cells with MLL rearrangement. Pediatr Blood Cancer 2011, 56:353-360.
16. Tait S.W., Parsons M.J., Llambi F., Bouchier-Hayes L., Connell S., Muñoz-Pinedo C., et al. Resistance to caspase-independent cell death requires persistence of intact mitochondria. Dev Cell 2010, 18:802-813.
17. Young K.W., Piñón L.G., Dhiraj D., Twiddy D., Macfarlane M., Hickman J., et al. Mitochondrial fragmentation and neuronal cell death in response to the Bcl-2/Bcl-x(L)/Bcl-w antagonist ABT-737. Neuropharmacology 2010, 58:1258-1267.
18. Hay FC, Westwood O, Nelson PN, Hudson L. Practical Immunology. Publ. Wiley Blackwell 2002.
19. Chou T.C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010, 70:440-446.
20. Jayanthan A., Howard S.C., Trippett T., Horton T., Whitlock J.A., Daisley L., et al. Targeting the Bcl-2 family of proteins in Hodgkin lymphoma: in vitro cytotoxicity, target modulation and drug combination studies of the Bcl-2 homology 3 mimetic ABT-737. Leuk Lymphoma 2009, 50:1174-1182.
21. Dole V.P. Addictive behavior. Sci Am 1980, 243:136-143.
22. Zhang H., Nimmer P.M., Tahir S.K., Chen J., Fryer R.M., Hahn K.R., et al. Bcl-2 family proteins are essential for platelet survival. Cell Death Differ 2007, 14:943-951.
23. Wilson W.H., O'Connor O.A., Czuczman M.S., LaCasce A.S., Gerecitano J.F., Leonard J.P., et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 2010, 11:1149-1159.
24. Frezza C., Cipolat S., Martins de Brito O., Micaroni M., Beznoussenko G.V., Rudka T., et al. OPA1 controls apoptotic cristae remodeling independently from mitochondrial fusion. Cell 2006, 126:177-189.
25. Li G., Miskimen K.L., Wang Z., Xie X.Y., Tse W., Gouilleux F., et al. Effective targeting of STAT5-mediated survival in myeloproliferative neoplasms using ABT-737 combined with rapamycin. Leukemia 2010, 24:1397-1405.
26. Cencic R., Carrier M., Trnkus A., Porco J.A., Minden M., Pelletier J. Synergistic effect of inhibiting translation initiation in combination with cytotoxic agents in acute myelogenous leukemia cells. Leuk Res 2010, 34:535-541.
27. Qian J., Zou Y., Rahman J.S., Lu B., Massion P.P. Synergy between phosphatidylinositol 3-kinase/Akt pathway and Bcl-xL in the control of apoptosis in adenocarcinoma cells of the lung. Mol Cancer Ther 2009, 8:101-109.
28. Li R., Zang Y., Li C., Patel N.S., Grandis J.R., Johnson D.E. ABT-737 synergizes with chemotherapy to kill head and neck squamous cell carcinoma cells via a Noxa-mediated pathway. Mol Pharmacol 2009, 75:1231-1239.
29. Säwe J. High-dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations of oral treatment. Clin Pharmacokinet 1986, 11:87-106.
30. Inturrisi C.E., Colburn W.A., Kaiko R.F., Houde R.W., Foley K.M. Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain. Clin Pharmacol Ther 1987, 41:392-401.
31. Konopleva M., Contractor R., Tsao T., Samudio I., Ruvolo P.P., Kitada S., et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 2006, 10:375-388.
32. Stewart M.L., Fire E., Keating A.E., Walensky L.D. The MCL-1 BH3 helix is an exclusive MCL-1 inhibitor and apoptosis sensitizer. Nat Chem Biol 2010, 6:595-601.
33. Keuling A.M., Felton K.E., Parker A.A., Akbari M., Andrew S.E., Tron V.A. RNA silencing of Mcl-1 enhances ABT-737-mediated apoptosis in melanoma: role for a caspase-8-dependent pathway. PLoS One 2009, 4:e6651.
34. Lestini B.J., Goldsmith K.C., Fluchel M.N., Liu X., Chen N.L., Goyal B., et al. Mcl1 downregulation sensitizes neuroblastoma to cytotoxic chemotherapy and small molecule Bcl2-family antagonists. Cancer Biol Ther 2009, 8:1587-1595.
35. Kile B.T. The role of the intrinsic apoptosis pathway in platelet life and death. J Thromb Haemost 2009, 7:214-217.
36. Vogler M., Dinsdale D., Sun X.M., Young K.W., Butterworth M., Nicotera P., et al. A novel paradigm for rapid ABT-737-induced apoptosis involving outer mitochondrial membrane rupture in primary leukemia and lymphoma cells. Cell Death Differ 2008, 15:820-830.
37. Sheridan C., Delivani P., Cullen S.P., Martin S.J. Bax- or Bak-induced mitochondrial fission can be uncoupled from cytochrome C release. Mol Cell 2008, 31:570-585.
38. Brooks C., Wei Q., Feng L., Dong G., Tao Y., Mei L., et al. Bak regulates mitochondrial morphology and pathology during apoptosis by interacting with mitofusins. Proc Natl Acad Sci U S A 2007, 104:11649-11654.
39. Tondera D., Grandemange S., Jourdain A., Karbowski M., Mattenberger Y., Herzig S., et al. SLP-2 is required for stress-induced mitochondrial hyperfusion. EMBO J 2009, 28:1589-1600.
40. Youle R.J., Narendra D.P. Mechanisms of mitophagy. Nat Rev Mol Cell Biol 2011, 12:9-14.
41. Perez-Alvarez S., Iglesias-Guimarais V., Solesio M.E., Melero-Fernandez de Mera R.M., Yuste V.J., et al. Methadone induces CAD degradation and AIF-mediated necrotic-like cell death in neuroblastoma cells. Pharmacol Res 2011, 63:352-360.
42. Beck M., Mirmohammadsadegh A., Franz B., Blanke J., Hengge U.R. Opioid receptors on white blood cells: effect of HIV infection and methadone treatment. Pain 2002, 98:187-194.
43. Beltran J.A., Peek J., Chang S.L. Expression and regulation of the mu opioid peptide receptor in TPA-differentiated HL-60 promyelocytic leukemia cells. Int Immunopharmacol 2006, 6:1331-1340.
44. Patrini G., Massi P., Ricevuti G., Mazzone A., Fossati G., Mazzucchelli I., et al. Changes in opioid receptor density on murine splenocytes induced by in vivo treatment with morphine and methadone. J Pharmacol Exp Ther 1996, 279:172-176.
45. Freedman M.H., Grunberger T., Correa P., Axelrad A.A., Dube I.D., Cohen A. Autocrine and paracrine growth control by granulocyte-monocyte colony-stimulating factor of acute lymphoblastic leukemia cells. Blood 1993, 81:3068-3075.
46. Ruoping T., Anne-Marie F., Jean-Yves P., Sabine D., Sylvie R., Florence A.C., et al. A new acute lymphoblastic leukaemia cell line BEL-1 with t(4; 11) (q21; q23) chromosomal translocation and a unique aberrant p27kip1 transcript. Br J Haematol 2004, 126:754-755.
47. Greil J., Gramatzki M., Burger R., Marschalek R., Peltner M., Trautmann U., et al. The acute lymphoblastic leukaemia cell line SEM with t(4;11) chromosomal rearrangement is biphenotypic and responsive to interleukin-7. Br J Haematol 1994, 86:275-283.
48. Inaba T., Roberts W.M., Shapiro L.H., Jolly K.W., Raimondi S.C., Smith S.D., et al. Fusion of the leucine zipper gene HLF to the E2A gene in human acute B-lineage leukemia. Science 1992, 257:531-534.